Completed PHASE2 INTERVENTIONAL 8-arm NCT03192176

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)

Sponsor: Astellas Pharma Global Development, Inc.

Conditions Hot Flashes Menopause

Interventions Fezolinetant Placebo

Updated 20 times since 2017 Last updated: Nov 11, 2024 Started: Jul 19, 2017 Primary completion: Sep 19, 2018 Completion: Sep 19, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03192176, this PHASE2 trial focuses on Hot Flashes and Menopause and remains completed. Sponsored by Astellas Pharma Global Development, Inc., it has been updated 20 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Dec 2024 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Dec 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 15 earlier versions

Oct 2021 — Oct 2023 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Oct 2019 — Oct 2020 [monthly]

Completed PHASE2
Jul 2019 — Oct 2019 [monthly]

Completed PHASE2
Dec 2018 — Jul 2019 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Aug 2018 — Dec 2018 [monthly]

Active Not Recruiting PHASE2
Jul 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE2
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Apr 2018 [monthly]

Recruiting PHASE2
Oct 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE2
Aug 2017 — Sep 2017 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2017 — Aug 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Global Development, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Atlanta, United States , Birmingham, United States , Champaign, United States , Charlottesville, United States , Cincinnati, United States , Clarksville, United States , Cleveland, United States , Columbus, United States , Crystal River, United States and 39 more locations